Participants with 1 or more serious adverse events · adults with severe Guillain‐Barré syndrome (GBS disability score > 2), within 2 weeks form onset
Eculizumab showed no clear difference in participants with 1 or more serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Time from randomisation until discontinuation of ventilation (for those ventilated) · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · patients with Guillain‐Barré syndrome
Interferon beta‐1a showed no clear difference in death compared with placebo (low certainty).
1 finding from 1 review
Death or disability after 12 months · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome
1 finding from 1 review
Improvement in disability grade Defined as achievement of a specified degree of improvement · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes improvement in disability grade Defined as achievement of a… compared with placebo (very low certainty).
1 finding from 1 review
In‐hospital postoperative mortality · Children having heart surgery with cardiopulmonary bypass
Glucocorticoid showed no clear difference in in‐hospital postoperative mortality compared with placebo (moderate certainty).
1 finding from 1 review
Duration of postoperative mechanical ventilation · Children having heart surgery with cardiopulmonary bypass
1 finding from 1 review
Length of postoperative ICU stay · Children having heart surgery with cardiopulmonary bypass
1 finding from 1 review
Length of postoperative hospital stay · Children having heart surgery with cardiopulmonary bypass
1 finding from 1 review
Mortality within the longest · Children having heart surgery with cardiopulmonary bypass
Glucocorticoid showed no clear difference in all‐cause mortality at longest compared with placebo (moderate certainty).
1 finding from 1 review
Cardiovascular mortality · Children having heart surgery with cardiopulmonary bypass
Glucocorticoid showed no clear difference in cardiovascular mortality at longest compared with placebo (moderate certainty).
1 finding from 1 review
Failure to separate from CPB · Children having heart surgery with cardiopulmonary bypass
Glucocorticoid showed no clear difference in failure to separate from CPB compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes all‐cause mortality: up to 3 months' (very low certainty).
1 finding from 1 review
Intervention not reported
Health‐related quality of life: up to 3 months ( · participants with alcoholic hepatitis at high risk of mortality and morbidity
The intervention showed no clear difference in health‐related quality of life: up to 3 months ( (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events during treatment · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes serious adverse events during treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Liver‐related mortality: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes liver‐related mortality: up to 3 months' (very low certainty).
1 finding from 1 review
Intervention not reported
Participants with any complication: up to 3 months following randomisation · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes participants with any complication: up to 3 months following… (very low certainty).
1 finding from 1 review
Intervention not reported
Participants with non‐serious adverse events: up to 3 months' · participants with alcoholic hepatitis at high risk of mortality and morbidity
It is very uncertain whether the intervention changes participants with non‐serious adverse events: up to 3 months' (very low certainty).
1 finding from 1 review